US 9127057
Anti-IL-23 heterodimer specific antibodies
granted A61KA61K2039/505A61P
Quick answer
US patent 9127057 (Anti-IL-23 heterodimer specific antibodies) held by TEVA PHARMACEUTICALS AUSTRALIA PTY LTD expires Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- TEVA PHARMACEUTICALS AUSTRALIA PTY LTD
- Grant date
- Tue Sep 08 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 16
- CPC classes
- A61K, A61K2039/505, A61P, A61P1/04, A61P17/06